Company Analysis Gilead Sciences
1. Summary
Advantages
- Dividends (2.81%) are higher than the sector average (0.5339%).
- The stock's return over the last year (40.2%) is higher than the sector average (-47.29%).
Disadvantages
- Price (127.12 $) is higher than fair price (6.89 $)
- Current debt level 45.28% has increased over 5 years from 39.9%.
- The company's current efficiency (ROE=2.28%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Gilead Sciences | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.7% | -35.1% | 0.4% |
| 90 days | 11.4% | -47.8% | 7.5% |
| 1 year | 40.2% | -47.3% | 17.4% |
GILD vs Sector: Gilead Sciences has outperformed the "Healthcare" sector by 87.49% over the past year.
GILD vs Market: Gilead Sciences has outperformed the market by 22.79% over the past year.
Stable price: GILD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GILD with weekly volatility of 0.773% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (127.12 $) is higher than the fair price (6.89 $).
Price is higher than fair: The current price (127.12 $) is 94.6% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (240.57) is higher than that of the sector as a whole (-274.25).
P/E vs Market: The company's P/E (240.57) is higher than that of the market as a whole (-80.5).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (6) is lower than that of the sector as a whole (256.7).
P/BV vs Market: The company's P/BV (6) is lower than that of the market as a whole (51.89).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (4.02) is lower than that of the sector as a whole (56.99).
P/S vs Market: The company's P/S indicator (4.02) is lower than that of the market as a whole (137.42).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (29.81) is higher than that of the sector as a whole (12.51).
EV/Ebitda vs Market: The company's EV/Ebitda (29.81) is higher than that of the market as a whole (-47.95).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 87.87% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (87.87%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.73%).
6.4. ROE
ROE vs Sector: The company's ROE (2.28%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (2.28%) is higher than that of the market as a whole (-10.25%).
6.6. ROA
ROA vs Sector: The company's ROA (0.7926%) is higher than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (0.7926%) is lower than that of the market as a whole (39.65%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (11.06%) is higher than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (11.06%) is higher than that of the market as a whole (8.73%).
8. Dividends
8.1. Dividend yield vs Market
High yield: The dividend yield of the company 2.81% is higher than the average for the sector '0.5339%.
8.2. Stability and increase in payments
Dividend stability: The company's dividend yield 2.81% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 2.81% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (816.25%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 10.5% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 28.11.2025 | Bluestone Jeffrey Director |
Sale | 125.08 | 62 540 | 5 000 |
| 28.11.2025 | Bluestone Jeffrey Director |
Purchase | 64.92 | 32 460 | 5 000 |
| 15.10.2025 | Mercier Johanna Chief Commercial Officer |
Sale | 118.08 | 35 424 | 3 000 |
| 15.10.2025 | Dickinson Andrew D Chief Financial Officer |
Sale | 118.08 | 29 520 | 2 500 |
| 15.10.2025 | JOHANNA MERCIER Officer |
Purchase | 118.08 | 35 424 | 3 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
